ProtOS

Company Overview

Snapshot

Founded in January 2023 by Yossi Pollak and Ofer Springer, ProtOS operates with 1–10 employees. The company has secured funding across one round from two investors, with Fresh Fund identified as a lead investor.

Business overview

ProtOS is an AI-first protein design company focused on developing therapeutics for diseases currently considered undruggable. The company leverages proprietary AI models to create novel bio-therapeutics that precisely interact with proteins-of-interest beyond the reach of traditional small molecules and antibodies. Its SHRED platform utilizes foundation models to design de-novo AI-proteins, specifically developing Biologic Targeted Protein Degraders that offer advantages over existing PROTAC and Molecular-Glue approaches. ProtOS operates within the Health Tech & Life Sciences sector, with a focus on Pharma & Medical Biotechnology and Drugs Discovery & Development, targeting the pharmaceutical industry.

Company Intelligence Q&A

When was ProtOS founded?

ProtOS was founded in January 2023 by co-founders Yossi Pollak and Ofer Springer.

What is the primary focus of ProtOS?

ProtOS is an AI-first protein design company developing therapeutics to treat undruggable diseases by leveraging proprietary AI models to create novel bio-therapeutics.

Which platform does ProtOS use for protein design?

ProtOS utilizes its SHRED platform, which employs foundation models to design de-novo AI-proteins for highly specific and effective degradation of undruggable targets.

How many employees does ProtOS currently have?

ProtOS currently operates with 1–10 employees.